CH Biotech R&D Co., Ltd. (TPE:6534)

Orchard Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,665	1,636	1,515	1,434	1,019	702.19
Revenue Growth (YoY)	8.18%	7.98%	5.63%	40.81%	45.05%	-16.47%
Cost of Revenue	272.79	270.92	254.73	299.52	170.56	112.18
Gross Profit	1,392	1,365	1,260	1,135	847.95	590.01
Selling, General & Admin	487.86	459.16	389	351.12	267.2	251.6
Research & Development	367.52	363.36	305.24	272.41	221.48	193.34
Operating Expenses	855.37	822.52	694.24	623.54	488.68	444.93
Operating Income	536.43	542.3	565.86	511.06	359.27	145.07
Interest Expense	-15.38	-15	-16.81	-16.81	-13.9	-22.74
Interest & Investment Income	15.75	18.8	17.22	5.12	0.6	1.52
Earnings From Equity Investments	-0.48	-0.26	-0.05	-	-	-
Currency Exchange Gain (Loss)	25.48	39.58	7.18	62.28	-12.15	-24.51
Other Non Operating Income (Expenses)	4.99	5.54	4.46	3.59	25.69	26.84
EBT Excluding Unusual Items	566.79	590.96	577.86	565.23	359.5	126.19
Gain (Loss) on Sale of Assets	0.39	0.31	1.07	0.57	0.11	0.04
Other Unusual Items	1.69	1.69	-	-	0.04	1.17
Pretax Income	568.87	592.96	578.93	565.8	359.65	127.39
Income Tax Expense	112.95	117.27	115.64	100.37	68.15	27.23
Earnings From Continuing Operations	455.92	475.69	463.29	465.42	291.5	100.16
Minority Interest in Earnings	0.79	0.7	-	-	-	-
Net Income	456.71	476.39	463.29	465.42	291.5	100.16
Net Income to Common	456.71	476.39	463.29	465.42	291.5	100.16
Net Income Growth	-6.70%	2.83%	-0.46%	59.66%	191.03%	-47.41%
Shares Outstanding (Basic)	103	103	97	97	97	97
Shares Outstanding (Diluted)	103	103	98	99	98	98
Shares Change (YoY)	4.38%	5.50%	-0.77%	0.54%	0.44%	-0.37%
EPS (Basic)	4.44	4.63	4.76	4.79	3.00	1.03
EPS (Diluted)	4.41	4.61	4.73	4.72	2.97	1.03
EPS Growth	-10.95%	-2.54%	0.21%	58.92%	189.44%	-47.08%
Free Cash Flow	314.35	-49.98	545.47	585.08	192.43	125.03
Free Cash Flow Per Share	3.04	-0.48	5.57	5.93	1.96	1.28
Dividend Per Share	4.100	4.100	4.090	3.880	1.304	0.435
Dividend Growth	0.24%	0.24%	5.41%	197.48%	199.98%	-52.27%
Gross Margin	83.61%	83.44%	83.18%	79.11%	83.25%	84.02%
Operating Margin	32.23%	33.15%	37.35%	35.64%	35.27%	20.66%
Profit Margin	27.44%	29.12%	30.58%	32.45%	28.62%	14.26%
Free Cash Flow Margin	18.88%	-3.06%	36.01%	40.80%	18.89%	17.80%
EBITDA	705.32	704.78	703.17	628.06	435.89	223.8
EBITDA Margin	42.37%	43.09%	46.42%	43.79%	42.80%	31.87%
D&A For EBITDA	168.9	162.48	137.31	117.01	76.62	78.73
EBIT	536.43	542.3	565.86	511.06	359.27	145.07
EBIT Margin	32.23%	33.15%	37.35%	35.64%	35.27%	20.66%
Effective Tax Rate	19.86%	19.78%	19.98%	17.74%	18.95%	21.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.